[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Sumitomo Pharma Co. Ltd.

Sumitomo Pharma highlights research in complex hematologic conditions from ASH2025, while also addressing patient concerns about medication access and insurance coverage.

### About Sumitomo Pharma Co. Ltd.
Sumitomo Pharma Co. Ltd. is a Japanese pharmaceutical company engaged in research, development, manufacturing, and marketing of pharmaceutical products.  

### Insights
- Sumitomo Pharma Co. Ltd. engagements is up XXXXX% from the previous week.
- Sumitomo Pharma Co. Ltd. mentions is up XXXXXX% from the previous year.

### Price: $
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/close.tsv)  
The stock price is likely declining due to negative market sentiment regarding potential tariffs and patient concerns about medication access, despite positive news about partnerships and financial results.  

1-Year High: $XXXXX on 2025-11-28  
1-Year Low: $XXX on 2025-04-16  
  
  
### AltRank: XXX
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/alt_rank.tsv)  
Sumitomo Pharma Co. Ltd. is currently AltRank #526 based on combined combined social and market metrics
Daily Average: XXXXX  
1-Year High: XXXXX on 2025-01-15  
1-Year Low: XXX on 2025-11-05  
  
  
### Galaxy Score: XX
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/galaxy_score.tsv)  
Current Value: XX  
Daily Average: XX  
1-Year High: XX on 2025-08-20  
1-Year Low: XX on 2024-12-21  
  
  
### Engagements: XXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/interactions.tsv)  
Current Value: XXX  
Daily Average: XXX  
X Week: XXXXX +16%  
X Month: XXXXX -XX%  
X Months: XXXXXX +74%  
X Year: XXXXXX +59%  
1-Year High: XXXXXX on 2025-08-05  
1-Year Low: X on 2024-12-24  

Engagements by network (24h):
X: XXX

  
  
### Mentions: X (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/posts_active.tsv)  
Current Value: X  
Daily Average: X  
X Week: XX +31%  
X Month: XX +14%  
X Months: XXX +20%  
X Year: XXX +136%  
1-Year High: XX on 2025-09-26  
1-Year Low: X on 2024-12-17  

Mentions by network (24h):
X: XX

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning Sumitomo Pharma Co. Ltd. in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X  
X Week: XX no change  
X Month: XX +4.80%  
X Months: XX +5.60%  
X Year: XXX +148%  
1-Year High: XX on 2025-09-26  
1-Year Low: X on 2024-12-17  

The most influential creators that mention Sumitomo Pharma Co. Ltd. in the last XX hours

| Creator                                            | Rank | Followers | Posts | Engagements |
| -------                                            | ---- | --------- | ----- | ----------- |
| [@SumitomoPharma](/creator/twitter/SumitomoPharma) | X    | XXX       | X     | XX          |

[View More](/list/creators/$4506t/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Month: XXX% no change  
X Months: XXX% no change  
X Year: XXX% no change  
1-Year High: XXX% on 2025-01-22  
1-Year Low: XX% on 2025-09-18  

Most Supportive Themes:
- Disease Awareness Campaigns: (30%) Sumitomo Pharma is actively involved in raising awareness for various health conditions, including fibroids and prostate cancer, through social media campaigns.
- Research and Development Updates: (25%) The company shares updates on its research into therapies for complex hematologic conditions, highlighting findings from conferences like ASH2025.
- Patient Testimonials and Medication Efficacy: (20%) Positive patient experiences with specific medications, such as Gemtesa for chronic kidney infections, are being shared, alongside concerns about insurance coverage.
  
Most Critical Themes:
- Market Expansion Reports: (15%) Reports indicate significant market expansion for conditions like Myelofibrosis, involving Sumitomo Pharma alongside other key players in the pharmaceutical industry.
- Insurance and Access Concerns: (10%) Patients express frustration with insurance coverage for Sumitomo Pharma's medications, highlighting a potential barrier to access despite treatment efficacy.
  
  
  
### Market Cap: $undefined
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$4506t/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$4506t/time-series/market_cap.tsv)  
Current Value: $undefined  
Daily Average: $XXXXXXXXXXXXXXX  
1-Year High: $XXXXXXXXXXXXXXX on 2025-02-17  
1-Year Low: $XXXXXXXXXXXXXXX on 2025-01-16  

### Top Sumitomo Pharma Co. Ltd. Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Sumitomo Pharma Presents New Clinical Data for Enzomenib and Nuvisertib at ASH 2025 🧬 At the American Society of Hematology (ASH) 2025 Annual Meeting Sumitomo Pharma shared new results for two investigational targeted therapies: enzomenib (menin inhibitor) and nuvisertib (PIM1 kinase inhibitor). 🔹 Key Findings Enzomenib monotherapy: ORR XXXX% CR/CRh XX% in AML with KMT2A rearrangement. Enzomenib + azacitidine/venetoclax: ORR XX% in treatment-nave AML. Nuvisertib: Demonstrated tolerability and symptom improvement in myelofibrosis. These data support continued development of both agents as"  
[X Link](https://x.com/stellanewslife/status/2000217525112742004) [@stellanewslife](/creator/x/stellanewslife) 2025-12-14T14:53Z XXX followers, XXX engagements


"Were excited to share new findings from #ASH2025 that highlight our research into therapies for patients with complex hematologic conditions. #SumitomoLife"  
[X Link](https://x.com/SumitomoPharma/status/1998076115395514587) [@SumitomoPharma](/creator/x/SumitomoPharma) 2025-12-08T17:04Z XXX followers, XXX engagements


"The 67th @American Society of Hematology (ASH) annual Meeting starts this week Follow SMPA for updates on our latest research and patient-focused innovations. #SumitomoLife"  
[X Link](https://x.com/SumitomoPharma/status/1997032690495656201) [@SumitomoPharma](/creator/x/SumitomoPharma) 2025-12-05T19:57Z XXX followers, XX engagements


"Happy Thanksgiving from all of us at SMPA Were grateful for our colleagues partners and the patients who inspire our work every day. Wishing everyone a healthy and safe holiday season. #SumitomoLife"  
[X Link](https://x.com/SumitomoPharma/status/1994059939275280506) [@SumitomoPharma](/creator/x/SumitomoPharma) 2025-11-27T15:05Z XXX followers, XX engagements